
Metabolism of Nucleotides




• Nucleic acid **metabolism** is the process by which nucleic acids (DNA and RNA) are synthesized and degraded. Nucleic acids are polymers of **nucleotides**.

• Nucleotide synthesis is an anabolic mechanism involving the chemical reaction of phosphate, pentose sugar, and a nitrogenous base.


Nucleoside and Nucleotide

Nucleoside = Nitrogenous base – ribose

Nucleotide = Nitrogenous base – ribose – phosphate




Purines vs Pyrimidines




Functions of Nucleotides

- Activated precursors of DNA & RNA.
- ATP Universal currency of energy.
- Required for activation of intermediates in many biosynthetic pathway.
- Carrier of methyl group in the form of SAM
- GTP-involved in protein biosynthesis as source of energy.
- · Components of coenzymes: NAD, FAD & CoA.
- Metabolic regulators, e.g. cAMP, cGMP.



• Synthesis of purine nucleotides



There are two pathways leading to nucleotides

- De novo synthesis: The synthesis of nucleotides begins with their metabolic precursors: <u>amino</u> <u>acids, ribose-5-phosphate, CO₂, and one-carbon</u> <u>units</u>.
- Salvage pathways: The synthesis of nucleotide by recycle the free bases or nucleosides released from nucleic acid breakdown.

Biosynthetic Routes: De novo and salvage pathways

- Most organisms can synthesize purine and pyrimidrne nucleotides from low-molecular-weight precursors in amounts sufficient for their needs. These so-called de novo pathways are essentially identical throughout the biological world.
- Salvage pathways involve the utilization of preformed purme and pyrimidine compounds that would be otherwise lost to biodegradation. Salvage pathways represent important sites for manipulation of biological systems.

De novo synthesis

• Site:

in cytosol of liver, small intestine and thymus

• Characteristics:

a. Purines are synthesized using 5phosphoribose(R-5-P) as the starting material step by step.

b. PRPP(5-phosphoribosyl-1-pyrophosphate) is active donor of R-5-P.

c. AMP and GMP are synthesized further at the base of IMP(Inosine-5'-Monophosphate).

Contd.

- The pathway can be divided into two stages.
- Stage one : formation of inosine monophosphate (IMP)

Stage two : conversion of IMP to either AMP or GMP

Stage One

PRPP synthetase R5P + ATP-----→PRPP + AMP

amidotransferase PRPP + Gln-----→PRA + Glu

JAYATI MISHRA

ROII No. 12

Contnd. Stage Two The conversion of IMP either to AMP or GMP requires two reactions. GTP,Mg++,adenylosuccinate synthase IMP + Asp------→adenylosuccinate adenylosuccinate lyase Adenylosuccinate------→AMP + fumarate

ROII No. 12

10

JAYATI MISHRA

Contd. IMP dehydrogenase IMP + H2O + NAD+----→XMP + NADH + H+ ATP, Mg++, GMP synthase XMP + Gln-----→GMP + Glu

Nucleoside triphosphates are the most common nucleotide used in metabolism.

ATP is synthesized from ADP and Pi via oxidative. phosphorylation or substrate level phosphorylation.

Contd.

ADP is synthesized from AMP in a reaction catalyzed by adenylate kinase.

Other NTPs are also synthesized in ATP-requiring reactions catalyzed by corresponding NMP kinases.

NMP + ATP-----→NDP + ADP

NDP kinase catalyzes the formation of NTP.



JAYATI MISHRA

Regulation of de novo Pathway PRPP activates amidotransferase.

IMP, AMP and GMP inhibit PRPP synthetase.

AMP inhibits conversion of IMP to GMP and GMP inhibits conversion of IMP to AMP.

ATP stimulates conversion of IMP to GMP and GTP stimulates conversion of IMP to AMP.

 That ensures a balanced synthesis of both families of purine nucleotides.


13

Salvage Pathway of Purine Nucleotides


Many cells have mechanisms to retrieve purine bases and purine nucleosides. They are used to synthesize purine nucleotides.


This is the salvage pathway.


14



Formation of AMP and GMP from IMP branch point







AR – andrenergic receptors.

Antimetabolites of purine nucleotides

- Antimetabolites of purine nucleotides are structural analogs of purine, amino acids and folic acid.
- They can interfere, inhibit or block synthesis pathway of purine nucleotides and further block synthesis of DNA, RNA, and proteins.
- Widely used to control cancer.

Antimetabolites of Purine Nucleotides

Antimetabolites of purine nucleotides are analogues of purine, amino acids or folic acid.

They either act as competitive inhibitors of enzymes in purine nucleotides synthesis or can be incorporated into purine nucleotides.

 Thus they block purine nucleotides synthesis or interfere in nucleic acids synthesis.

JAYATIMISHRA

Contd.

6-MP and 6-MG are purine analogues

6-MP nucleotide is structurally similar to IMP and inhibits conversion of IMP to AMP and GMP.

It also blocks synthesis of PRA from PRPP,, synthesis of GMP and IMP from G and H respectively.

Contd.

 Azaserine and diazonorleucine are amino acid analogues.

They are analogues of Gln and interfere with Gln in purine nucleotide de novo synthesis.


ROII No. 12

JAYATI MISHRA

2. Salvage pathway

- Purine bases created by degradation of RNA or DNA and intermediate of purine synthesis directly converted to the corresponding nucleotides.
- The significance of salvage pathway :
 - Save the fuel.
 - Some tissues and organs such as brain and bone marrow are only capable of synthesizing nucleotides by salvage pathway.
- Two phosphoribosyl transferases are involved:
 - APRT (adenine phosphoribosyl transferase) for adenine.
 - HGPRT (hypoxanthine guanine phosphoribosyl transferase) for guanine or hypoxanthine.

Purine Salvage Pathway



Absence of activity of HGPRT leads to Lesch-Nyhan syndrome.

Lesch-Nyhan syndrome


- first described in 1964 by Michael Lesch and William L. Nyhan.
- there is a defect or lack in the HGPRT enzyme
- Sex-linked metabolic disorder: only males
- the rate of purine synthesis is increased about 200-fold
 - Loss of HGPRT leads to elevated PRPP levels and stimulation of de novo purine synthesis.
- uric acid level rises
- in addition there are mental aberrations
- patients will self-mutilate by biting lips and fingers off

Lesch-Nyhan syndrome






DEGRADATION OF PURINE NUCLEOTIDES



Uric acid


- Uric acid is the <u>excreted end product of purine</u> catabolism in primates, birds, and some other animals.
- The rate of uric acid excretion by the normal adult human is about 0.6 g/24 h, arising in part from ingested purines and in part from the turnover of the purine nucleotides of nucleic acids.
- The normal concentration of uric acid in the serum of adults is in the range of 3-7 mg/dl.

GOUT




Sodium Urate Crystals


- The disease gout, is a disease of the joints, usually in males, caused by an elevated concentration of uric acid in the blood and tissues.
- The joints become inflamed, painful, and arthritic, owing to the abnormal deposition of crystals of sodium urate.
- The kidneys are also affected, because excess uric acid is deposited in the kidney tubules.



<u>Gout, Urate crystallization</u>

in joints, soft tissue, cartilage and kidney








Advanced Gout Clinically Apparent Tophi










• SYNTHESIS OF PYRIMIDINE NUCLEOTIDES

De novo synthesis


- shorter pathway than for purines
- Pyrimidine ring is made first, then attached to ribose-P (unlike purine biosynthesis)
- only 2 precursors (aspartate and glutamine, plus HCO₃-) contribute to the 6-membered ring
- requires 6 steps
- the product is **UMP** (uridine monophosphate)


Step 1: synthesis of carbamoyl phosphate




Carbamoyl phosphate synthetase(CPS) exists in 2 types:
CPS-I, a mitochondrial enzyme, is dedicated to the <u>urea</u> cycle and arginine biosynthesis.
CPS-II, a cytosolic enzyme, used here. It is the committed step in animals.

Step 2: synthesis of carbamoyl aspartate






Step 4: oxidation of dihydroorotate to orotate




Step 5: acquisition of ribose phosphate moiety



Step 6: decarboxylation of OMP

SYNTHESIS OF PYRIMIDINE NUCLEOTIDES

Garrett/Grisham, Biochemistry with a Human Focus Figure 21.36



Orotidine 5'-Monophosphate (OMP)

Harcourt, Inc. items and derived items copyright © 2002 by Harcourt, Inc.